Fluconazole in vitro susceptibility test results determined by the CLSI M44-A disk diffusion method for 11,240 isolates of noncandidal yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2007. Data were collected for 8,717 yeast isolates tested with voriconazole from 2001 through 2007. A total of 22 different species/organism groups were isolated, of which Cryptococcus neoformans was the most common (31.2 % of all isolates). Overall, Cryptococcus (32.9%), Saccharomyces (11.7%), Tricho-sporon (10.6%), and Rhodotorula (4.1%) were the most commonly identified genera. The overall percentages of isolates in each category (susceptible, susceptible dose dependent, and resistant) were 78.0%, 9.5%, and 12.5% an...
The ARTEMIS Global Antifungal Susceptibility Program provides the collection of epidemiological data...
National Committee for Clinical Laboratory Standards (NCCLS) standard guidelines are available for t...
The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has ...
Fluconazole in vitro susceptibility test results determined by the CLSI M44-A disk diffusion method ...
From June 1997 to December 2001, results of in vitro susceptibility tests of yeast isolates from 35 ...
ABSTRACT From June 1997 to December 2001, results of in vitro susceptibil...
Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study si...
Fluconazole in vitro susceptibility test results for 140,767 yeasts were collected from 127 particip...
We conducted active, laboratory-based surveillance for isolates from patients with invasive infectio...
The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has ...
We evaluated all Candida spp. isolates obtained from patients admitted to two tertiary care hospital...
From June 1997 to December 2001, results of in vitro susceptibility tests of yeast isolates from 35 ...
Fluconazole susceptibility was tested in 385 clinical yeast isolates (285 Candida albicans, 38 C. gl...
An improved fluconazole 25-mg disk diffusion method was used to test the susceptibility of 20,900 co...
This is the first multi-centre study regarding yeast infections in Romania. The aim was to determine...
The ARTEMIS Global Antifungal Susceptibility Program provides the collection of epidemiological data...
National Committee for Clinical Laboratory Standards (NCCLS) standard guidelines are available for t...
The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has ...
Fluconazole in vitro susceptibility test results determined by the CLSI M44-A disk diffusion method ...
From June 1997 to December 2001, results of in vitro susceptibility tests of yeast isolates from 35 ...
ABSTRACT From June 1997 to December 2001, results of in vitro susceptibil...
Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study si...
Fluconazole in vitro susceptibility test results for 140,767 yeasts were collected from 127 particip...
We conducted active, laboratory-based surveillance for isolates from patients with invasive infectio...
The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has ...
We evaluated all Candida spp. isolates obtained from patients admitted to two tertiary care hospital...
From June 1997 to December 2001, results of in vitro susceptibility tests of yeast isolates from 35 ...
Fluconazole susceptibility was tested in 385 clinical yeast isolates (285 Candida albicans, 38 C. gl...
An improved fluconazole 25-mg disk diffusion method was used to test the susceptibility of 20,900 co...
This is the first multi-centre study regarding yeast infections in Romania. The aim was to determine...
The ARTEMIS Global Antifungal Susceptibility Program provides the collection of epidemiological data...
National Committee for Clinical Laboratory Standards (NCCLS) standard guidelines are available for t...
The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has ...